|1.||Losonsky, Genevieve A: 5 articles (12/2015 - 04/2009)|
|2.||Griffin, M Pamela: 3 articles (12/2015 - 08/2011)|
|3.||Jensen, Kathryn M: 3 articles (12/2015 - 08/2011)|
|4.||Harris, Brian S: 3 articles (12/2015 - 08/2011)|
|5.||Motavizumab Study Group: 3 articles (07/2014 - 04/2009)|
|6.||Harris, Brian: 2 articles (01/2010 - 04/2009)|
|7.||Connor, Edward M: 2 articles (01/2010 - 04/2009)|
|8.||Reid, Raymond: 1 article (12/2015)|
|9.||Jafri, Hasan S: 1 article (12/2015)|
|10.||Santosham, Mathuram: 1 article (12/2015)|
|1.||Respiratory Tract Infections (Respiratory Tract Infection)
12/01/2015 - "We aimed to assess the safety and efficacy of an anti-RSV monoclonal antibody (motavizumab) in healthy term (≥36 weeks' gestational age) infants for the prevention of medically attended RSV acute lower respiratory tract infections. "
07/01/2014 - "This study was conducted to determine whether treatment with motavizumab, an anti-respiratory syncytial virus (RSV) monoclonal antibody, would decrease viral load and improve clinical outcomes in previously healthy term infants hospitalized with RSV lower respiratory tract infection. "
07/01/2014 - "Motavizumab had no appreciable effect on RSV viral load measured in the upper respiratory tract of children hospitalized for RSV lower respiratory tract infection. "
07/01/2014 - "Infants hospitalized with lower respiratory tract infection and a positive RSV test performed locally were randomized to receive 1 intravenous dose of motavizumab (30 or 100 mg/kg) or placebo. "
04/01/2009 - "In phase III clinical trials, motavizumab was non-inferior [corrected] to palivizumab in reducing the incidence [corrected] of RSV-related hospitalizations and was superior to palivizumab in reducing the incidence [corrected] of RSV-related medically attended [corrected] outpatient visits for lower respiratory tract infections in high-risk infants. "
07/01/2014 - "Motavizumab treatment of infants hospitalized with respiratory syncytial virus infection does not decrease viral load or severity of illness."
10/01/2009 - "Motavizumab for the prevention of respiratory syncytial virus infection in infants."
04/01/2009 - "Safety, tolerability, pharmacokinetics, and immunogenicity of motavizumab, a humanized, enhanced-potency monoclonal antibody for the prevention of respiratory syncytial virus infection in at-risk children."
04/01/2009 - "Motavizumab, a second-generation humanized mAb for the prevention of respiratory syncytial virus infection in high-risk populations."
05/04/2007 - "Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract."
|3.||Lung Diseases (Lung Disease)
04/01/2009 - "In season 1, premature infants aged < or =6 months or children < or =24 months with chronic lung disease of prematurity received monthly motavizumab (3 or 15 mg/kg). "
01/01/2010 - "This randomized, double-blind, multinational, phase 3, noninferiority trial assessed safety and RSV hospitalization in 6635 preterm infants aged <or=6 months at enrollment or children aged <or=24 months with chronic lung disease of prematurity who received 15 mg/kg palivizumab or motavizumab monthly. "
|4.||Respiratory Sounds (Crackle)
12/01/2015 - "There was no effect on rates of medically attended wheezing in children aged 1-3 years (190 [14·9%] of participants randomly assigned to receive motavizumab vs 90 [14·0%] participants randomly assigned to receive placebo). "
07/01/2014 - "No differences were observed for duration of hospitalization, severity of illness measures or wheezing episodes during 12-month follow up in children treated with motavizumab or placebo."
04/01/2012 - "The MEDLINE/PubMed, EMBASE, and Cochrane databases were queried from January 1980 to December 2011 for articles in English using these associated search terms: respiratory syncytial virus, ribavirin, intravenous immunoglobulin, IVIG, palivizumab, motavizumab, lung, pneumonia, transplantation, bone marrow, cancer, malignancy, and vaccine. "
|2.||Intravenous Immunoglobulins (IVIG)
|6.||Anti-Inflammatory Agents (Anti-Inflammatories)
|7.||respiratory syncytial virus immune globulin intravenous
|1.||Bone Marrow Transplantation (Transplantation, Bone Marrow)